{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"22"},{"groupId":"OG006","value":"42"},{"groupId":"OG007","value":"13"},{"groupId":"OG008","value":"6"}],"units":"Participants"}],"description":"An adverse event was defined as any untoward medical occurrence in a participant administered study treatment and did not necessarily have a causal relationship with this treatment. An adverse event could be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that was temporally associated with the use of the study treatment was also an adverse event.","groups":[{"description":"Participants received pembrolizumab 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.","id":"OG000","title":"Cohort 1: Myelodysplastic Syndrome (MDS)"},{"description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle OR 10 mg/kg by IV infusion on Day 1 of each 14-day cycle.","id":"OG001","title":"Cohort 2: Relapsed Refractory/Refractory (rR/R) Multiple Myeloma (MM)"},{"description":"Participants received pembrolizumab 10 mg/kg by IV infusion on Day 1 of each 14-day cycle.","id":"OG002","title":"Cohort 3: Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)"},{"description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle OR 10 mg/kg by IV infusion on Day 1 of each 14-day cycle.","id":"OG003","title":"Cohort 4A: R/R Primary Mediastinal B-cell Lymphoma (PMBCL)"},{"description":"Participants received pembrolizumab 10 mg/kg by IV infusion on Day 1 of each 14-day cycle.","id":"OG004","title":"Cohort 4B: Other Non-Hodgkin Lymphoma: Grey Zone, Splenic Marginal Zone, and Mantle Cell Lymphomas"},{"description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle.","id":"OG005","title":"Cohort 4C: R/R Follicular Lymphoma (FL)"},{"description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle.","id":"OG006","title":"Cohort 4D: R/R Diffuse Large B-Cell Lymphoma (DLBCL)"},{"description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle + lenalidomide 20 mg orally (PO) every day (QD) for 21 consecutive days with 7 days off within 28-day cycles. The 20 mg dose of lenalidomide is the RP2D.","id":"OG007","title":"Cohort 5: R/R DLBCL Pembrolizumab+Lenalidomide 20 mg (RP2D)"},{"description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle + lenalidomide 25 mg PO QD for 21 consecutive days with 7 days off within 28-day cycles.","id":"OG008","title":"Cohort 5: R/R DLBCL Pembrolizumab+Lenalidomide 25 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants who received at least 1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 78.5 months","title":"Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)","type":"PRIMARY","unitOfMeasure":"Participants"}